<DOC>
	<DOC>NCT02337387</DOC>
	<brief_summary>The purpose of this study is to evaluate the tolerability of two different formulations of blosozumab in women who have reached menopause. This study will last approximately 12 weeks for each participant, not including screening. Screening is required within 28 days prior to starting the study.</brief_summary>
	<brief_title>A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<criteria>Part A: Overtly healthy postmenopausal (PMP) females Part B: PMP women who are currently taking oral bisphosphonates for prevention or treatment of osteoporosis Have a body mass index (BMI) at screening of 19.0 to 35.0 kilogram per square meter (kg/m^2) Have known allergies to blosozumab, its constituents, or related compounds Have an abnormality in the 12lead electrocardiogram (ECG) History of breast carcinoma Fracture of a long bone within 1 year of screening Have used teriparatide within 3 years prior to screening</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>